World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 4, Number 6, December 2013, pages 221-229

Comparison of Neoadjuvant Intraarterial Chemotherapy Versus Concurrent Chemoradiotherapy in Patients With Stage IIIB Uterine Cervical Cancer

Figure 2. Kaplan-Maier estimates of overall survival for patients who received IA-NAC or CCRT. The 5-year survival rate was 62.4% with IA-NAC and 51.1% with CCRT.

Figure 3. Kaplan-Maier estimates of disease-free survival for patients who received IA-NAC or CCRT. The 5-year survival rate was 44.5% with IA-NAC and 46.9% with CCRT.

Figure 4. Kaplan-Maier estimates of overall survival for patients who received IA-NAC + ARH or IA-NAC + RT. The 5-year survival rate was 75.0% with IA-NAC and 55.3% with CCRT.

Figure 5. Kaplan-Maier estimates of disease-free survival for patients who received IA-NAC + ARH or IA-NAC + RT. The 5-year survival rate was 58.3% with IA-NAC and 37.6% with CCRT.

**Table 1.** Clinical Characteristics of All the Patients With Stage IIIB Cervical Cancer
	IA-NAC group (n = 38)	CCRT group (n = 38)	P value
Age (years)
Mean ± SD	56.2 ± 9.0	58.9 ± 12.4	0.612
ECOG performance status (n, %)
0	37 (97.4%)	60 (93.5%)	0.857
1-2	1 (2.6%)	4 (6.5%)
Tumor dimension (mm)
Mean ± SD	55.6 ± 16.7	47.5 ± 14.9	0.012
Pelvic lymph node status (n, %)
Negative	23 (60.5%)	54 (84.4%)	0.071
Positive	15 (39.5%)	11 (17.2%)
Serum SCC (ng/ML)
Mean ± SD	25.1 ± 33.0	24.1 ± 38.8	0.893

Table 1. Clinical Characteristics of All the Patients With Stage IIIB Cervical Cancer

IA-NAC group (n = 38)

CCRT group (n = 38)

P value

Age (years)

Mean ± SD

56.2 ± 9.0

58.9 ± 12.4

0.612

ECOG performance status (n, %)

37 (97.4%)

60 (93.5%)

0.857

1-2

1 (2.6%)

4 (6.5%)

Tumor dimension (mm)

Mean ± SD

55.6 ± 16.7

47.5 ± 14.9

0.012

Pelvic lymph node status (n, %)

Negative

23 (60.5%)

54 (84.4%)

0.071

Positive

15 (39.5%)

11 (17.2%)

Serum SCC (ng/ML)

Mean ± SD

25.1 ± 33.0

24.1 ± 38.8

0.893

**Table 2.** Clinical Characteristics Patients With Treated With IA-NAC
	ARH group (n = 12)	RT group (n = 26)	P value
Age (years)
Mean ± SD	53.7 ± 8.6	57.3 ± 9.1	0.246
ECOG performance status (n, %)
0	12 (100%)	26 (93.5%)	0.857
1-2	0 (0%)	1(6.5%)
Tumor dimension (mm)
Mean ± SD	53.8 ± 1637	56.4 ± 17.2	0.659
Pelvic lymph node status (n, %)
Negative	7 (58.3%)	16 (61.5%)	0.583
Positive	5 (41.7%)	10 (38.5%)
Serum SCC (ng/ML)
Mean ± SD	10.9 ± 10.2	31.6 ± 37.7	0.073

Table 2. Clinical Characteristics Patients With Treated With IA-NAC

ARH group (n = 12)

RT group (n = 26)

P value

Age (years)

Mean ± SD

53.7 ± 8.6

57.3 ± 9.1

0.246

ECOG performance status (n, %)

12 (100%)

26 (93.5%)

0.857

1-2

0 (0%)

1(6.5%)

Tumor dimension (mm)

Mean ± SD

53.8 ± 1637

56.4 ± 17.2

0.659

Pelvic lymph node status (n, %)

Negative

7 (58.3%)

16 (61.5%)

0.583

Positive

5 (41.7%)

10 (38.5%)

Serum SCC (ng/ML)

Mean ± SD

10.9 ± 10.2

31.6 ± 37.7

0.073

**Table 3.** Response to IA-NAC or CCRT
	IA-NAC group (n = 38)	CCRT group (n = 64)
Complete response	15	39.4	26	40.6
Partial response	18	47.4	37	57.8
Stable disease	5	13.2	1	1.6
Response rate	33	86.8	63	98.4

Table 3. Response to IA-NAC or CCRT

IA-NAC group (n = 38)

CCRT group (n = 64)

No. of patients

Complete response

39.4

40.6

Partial response

47.4

57.8

Stable disease

13.2

1.6

Response rate

86.8

98.4

**Table 4.** The Patterns of Failure and Death
Outcome	IA-NAC group (n = 38)	CCRT group (n = 64)
Progression status
Relapse	20		33
Local	9	23.7	22	34.3
Distant	9	23.7	6	9.3
Combined	2	5.2	2	3.1
No evidence of disease	18	47.4	31	48.3

Survival status
Dead	17	44.7	34	53.1
Alive	21	55.3	30	46.9

Table 4. The Patterns of Failure and Death

Outcome

IA-NAC group (n = 38)

CCRT group (n = 64)

No. of patients

Progression status

Relapse

Local

23.7

34.3

Distant

23.7

9.3

Combined

5.2

3.1

No evidence of disease

47.4

48.3

Survival status

Dead

44.7

53.1

Alive

55.3

46.9